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Since the first report (1) low number of monozygotic twin pairs with concordant leukemia has been described (2) . The interval between the onsets of overt disease in each of the twins is variable usually from some months to some years (2) . Genetic changes in childhood acute leukemia are highly variable and patient specific (clone-specific genomic breakpoints and somatic mutations), therefore finding of shared unique mutation in monozygotic twins would imply the monoclonal origin in one fetus in utero (2, 3, 4) . In patients with acute myeloblastic leukemia (AML), mutations in CCAAT-enhancer-binding-proteinα (C/EBPa) are common, occurring in 5-14% of patients (8) and germline mutations in CEBPA gene have been described (5, 6 ). We present a unique case of monozygotic and monohorionic twins who developed AML with unusually long difference of disease onset, in which we investigated the genetic background.
Twin A was diagnosed with M1-AML at the age of 21 months. GTG banding revealed normal karyotype. She was treated according to AML-BFM 83 protocol followed by syngenic bone marrow transplantation (BMT). She is in the first complete remission (CR) 19 years later. Twin B was diagnosed with M1-AML at the age of 15 years. GTG banding revealed normal kariotype.
She was treated according to AML-BFM 98 protocol and is in the first CR 5 years later. Normal kariotype and favorable outcome prompted us to search for CEBPA gene mutations. DNA was isolated from bone marrow smears of both patients at the time of diagnosis and from buccal swaps and peripheral blood in CR. The CEBPA gene was PCR amplified and direct sequenced with ABI-PRISM 310 sequencer. Molecular studies were negative for FLT3-ITD, NPM1 mutations for both twins.
Both twins carried a germline N-terminal frameshift CEBPA mutation, a 19-base pair deletion (c.147_165del, p.Glu50fs) (Fig.1A) . Interestingly, at the time of diagnosis of AML both twins carried an additional identical somatic C-terminal mutation: an inframe insertion of aminoacid lysine (c.936_937dupAAG, p.313_314insLys) (Fig.1B) . Twin A, also had the third mutation in C-terminal part of CEBPA gene, somatic inframe deletion of 50 aminoacids (c.911_1060del, p.304-353del) (Fig.1C) . At present time DNA from buccal swaps and peripheral blood were examined and while the germline CEBPA mutation was found in both twins, we did not find either of somatic mutations.
According to the accepted hypothesis, concordant leukemia arises as a consequence of intraplacental spread of an initiated preleukemic clone from one twin to the other. The transcription factor C/EBPα is a regulator of myeloid development, directing granulocyte and monocyte differentiation. Finding suggests that CEBPA germline mutation predispose to the development of leukemia and that the second "hit" is an acquired mutation in the remaining CEBPA allele (5). Sporadic mutations in CEBPA occur in patients with AML (7) and can be categorized into 2 types. N-terminal frameshift mutations result in expression of a truncated dominant negative C/EBPαp30 isoform. C-terminal in-frame insertions or deletions result in alteration of the leucine zipper domain preventing dimerisation of transcription factor and DNA binding (8, 9) . Most AML patients with CEBPA mutations have both mutations simultaneously and display a favorable outcome (9, 10) . It was shown in families where several members had the same germline CEBPA mutation and different somatic CEBPA mutations that somatic mutations represented the second event for development of AML (5, 6) . At the time of diagnosis, twins shared in addition to the CEBPA germline mutation also the same somatic CEBPA mutation, namely inframe insertion of lysine (p.313_314insLys), which has not been described in the literature. It is hard to speculate that a common mechanism for development of this somatic mutation exists. We suspect that this mutation has arisen in one twin and has been intraplacentaly transferred to other twin in utero. The interval between AML appearances in our twins is considerably longer than reported elsewhere. The syngenic bone marrow donor twin developed AML 13 years after the diagnosis of her twin. Both sisters still carry germline CEBPA mutation and are therefore at risk for the second hit and development of novel AML.
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The implications of this knowledge is debatable -some authors (5) propose that BMT should be considered in patients with AML with germline CEBPA mutation to replace the mutated hematopoetic stem cells and eliminate the risk of subsequent C-terminal somatic mutations and secondary AML. However, it seems clear that molecular scrutiny of the healthy monozygotic cotwin is relevant if the individual is considered as a bone marrow donor for a twin with leukemia.
Therefore, in monozygotic twins, we propose searching for germline CEBPA mutations before considering syngenic BMT. 
